{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T05:14:25Z","timestamp":1783314865226,"version":"3.54.6"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Finotonlimab combined with bevacizumab demonstrated superior progression-free survival and overall survival compared with sorafenib in patients with unresectable hepatocellular carcinoma. However, its economic value in different healthcare systems has not been fully characterized. This study evaluated the cost-effectiveness of finotonlimab plus bevacizumab from the perspectives of U.S. payers and the Chinese healthcare system. A Markov state-transition model was constructed using clinical efficacy data from a phase 3 randomized controlled trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Health state utilities were obtained directly from trial data, and cost inputs were derived from published sources and country-specific charge databases. The outcomes included quality-adjusted life years (QALYs), incremental cost-effectiveness ratios (ICERs), incremental net health benefits (INHBs), and incremental net monetary benefits (INMBs). Scenario analyses, deterministic and probabilistic sensitivity analyses, and price simulations were performed to assess the robustness and cost-effectiveness across predefined willingness-to-pay (WTP) thresholds.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the base-case analysis, the ICER of finotonlimab plus bevacizumab compared with sorafenib was $27,505.33 per QALY in China and $138,055.71 per QALY in the U.S., both below the corresponding WTP thresholds of $40,354.27 and $150,000 per QALY, respectively. The associated INHBs were 0.26 QALYs in China and 0.07 QALYs in the U.S., with INMBs of $10,523.82 and $10,684.73, respectively. Probabilistic sensitivity analysis indicated that combination therapy was cost-effective in 91.43% of simulations in China and 58.33% in the United States. Price simulation analyses suggested that finotonlimab would remain cost-effective in the U.S. setting when priced below $9,157.84 per 200\u202fmg.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>From both Chinese and U.S. payer perspectives, finotonlimab plus bevacizumab represents a cost-effective first-line treatment strategy for unresectable hepatocellular carcinoma. These findings offer quantitative support for pricing and reimbursement decisions related to this emerging immunotherapy combination targeted therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpubh.2026.1781790","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T04:21:04Z","timestamp":1783311664000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Economic value of finotonlimab plus bevacizumab versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma in China and the United States"],"prefix":"10.3389","volume":"14","author":[{"given":"Yulong","family":"He","sequence":"first","affiliation":[{"name":"Department of Oncology, Nanxishan Hospital of Guangxi Zhuang Autonomous Region","place":["Guilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinling","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Nanxishan Hospital of Guangxi Zhuang Autonomous Region","place":["Guilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Oncology, Nanxishan Hospital of Guangxi Zhuang Autonomous Region","place":["Guilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Oncology, Nanxishan Hospital of Guangxi Zhuang Autonomous Region","place":["Guilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinrong","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Nanxishan Hospital of Guangxi Zhuang Autonomous Region","place":["Guilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijian","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, Nanxishan Hospital of Guangxi Zhuang Autonomous Region","place":["Guilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenwang","family":"Lang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Nanxishan Hospital of Guangxi Zhuang Autonomous Region","place":["Guilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global Cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/s0140-6736(25)01042-6","article-title":"The lancet commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment","volume":"406","author":"Chan","year":"2025","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1007\/s12672-025-03174-y","article-title":"Global burden of liver Cancer attributable to drug use: trends from 1990 to 2021 and projections to 2040","volume":"16","author":"Chen","year":"2025","journal-title":"Discov Oncol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1002\/ijc.34724","article-title":"Incidence trends of primary liver Cancer in different geographical regions of China from 1978 to 2012 and projections to 2032: an age-period-cohort analysis","volume":"154","author":"Jiang","year":"2024","journal-title":"Int J Cancer"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1001\/jamaoncol.2023.4003","article-title":"Tislelizumab vs sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a phase 3 randomized clinical trial","volume":"9","author":"Qin","year":"2023","journal-title":"JAMA Oncol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1200\/jco.19.01307","article-title":"Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in Keynote-240: a randomized, double-blind, phase III trial","volume":"38","author":"Finn","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/s1470-2045(21)00151-0","article-title":"Patient-reported outcomes with Atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial","volume":"22","author":"Galle","year":"2021","journal-title":"Lancet Oncol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/s1470-2045(21)00252-7","article-title":"Sintilimab plus a bevacizumab biosimilar (Ibi305) versus sorafenib in unresectable hepatocellular carcinoma (Orient-32): a randomised, open-label, phase 2-3 study","volume":"22","author":"Ren","year":"2021","journal-title":"Lancet Oncol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1016\/s1470-2045(25)00543-1","article-title":"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (Cares-310): final analysis of a randomised, open-label, international, phase 3 study","volume":"26","author":"Qin","year":"2025","journal-title":"Lancet Oncol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/s2468-1253(25)00059-7","article-title":"Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial","volume":"10","author":"Shi","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/s1470-2045(25)00190-1","article-title":"Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (Apollo): a randomised, controlled, phase 3 trial","volume":"26","author":"Zhou","year":"2025","journal-title":"Lancet Oncol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ph18030395","article-title":"Preclinical characterization of efficacy and pharmacodynamic properties of finotonlimab, a humanized anti-Pd-1 monoclonal antibody","volume":"395","author":"Yao","year":"2025","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"2568","DOI":"10.1038\/s41591-024-03110-7","article-title":"Finotonlimab with chemotherapy in recurrent or metastatic head and neck cancer: a randomized phase 3 trial","volume":"30","author":"Shi","year":"2024","journal-title":"Nat Med"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.21037\/tlcr-24-1042","article-title":"Efficacy and safety of finotonlimab plus docetaxel vs. docetaxel in previously treated advanced squamous cell non-small-cell lung cancer: a randomized, double-blinded, phase III trial","volume":"14","author":"Han","year":"2025","journal-title":"Transl Lung Cancer Res"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s41392-025-02333-5","article-title":"Finotonlimab (Pd-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2\/3 trial","volume":"10","author":"Zhao","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"397","DOI":"10.2165\/00019053-199813040-00003","article-title":"An introduction to Markov modelling for economic evaluation","volume":"13","author":"Briggs","year":"1998","journal-title":"PharmacoEconomics"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s40258-022-00743-y","article-title":"Correction to: consolidated health economic evaluation reporting standards 2022 (Cheers 2022) statement: updated reporting guidance for health economic evaluations","volume":"20","author":"Husereau","year":"2022","journal-title":"Appl Health Econ Health Policy"},{"key":"ref20","year":"2026"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000546574","article-title":"China liver Cancer guidelines for the diagnosis and treatment of hepatocellular carcinoma (2024 edition)","volume":"14","author":"Zhou","year":"2025","journal-title":"Liver Cancer"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1001\/jama.2020.0734","article-title":"Us health care spending by payer and health condition, 1996-2016","volume":"323","author":"Dieleman","year":"2020","journal-title":"JAMA"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.vhri.2020.07.580","article-title":"Current development and practice of Pharmacoeconomic evaluation guidelines for universal health coverage in China","volume":"24","author":"Yue","year":"2021","journal-title":"Value Health Reg Issues"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s40259-023-00586-6","article-title":"Serplulimab plus chemotherapy vs chemotherapy for treatment of us and Chinese patients with extensive-stage small-cell lung Cancer: a cost-effectiveness analysis to inform drug pricing","volume":"37","author":"Shao","year":"2023","journal-title":"BioDrugs"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1002\/(sici)1099-1050(200004)9:3<235::aid-hec502>3.0.co;2-o","article-title":"Development of who guidelines on generalized cost-effectiveness analysis","volume":"9","author":"Murray","year":"2000","journal-title":"Health Econ"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1177\/0272989x12472398","article-title":"Survival analysis for economic evaluations alongside clinical trials--extrapolation with patient-level data: inconsistencies, limitations, and a practical guide","volume":"33","author":"Latimer","year":"2013","journal-title":"Med Decis Mak"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1038\/s41416-018-0302-8","article-title":"Assessment of proportional hazard assumption in aggregate data: a systematic review on statistical methodology in clinical trials using time-to-event endpoint","volume":"119","author":"Rulli","year":"2018","journal-title":"Br J Cancer"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s40273-022-01227-6","article-title":"Cost-effectiveness analysis of a new second-line treatment regimen for advanced intrahepatic cholangiocarcinoma: biomarker-driven targeted therapy of pemigatinib versus 5-Fu chemotherapy","volume":"41","author":"Chueh","year":"2023","journal-title":"PharmacoEconomics"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1461571","DOI":"10.3389\/fphar.2024.1461571","article-title":"Cost-effectiveness analysis of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced gastric or gastroesophageal junction adenocarcinoma: perspectives from the United States and China","volume":"15","author":"Lang","year":"2024","journal-title":"Front Pharmacol"},{"key":"ref30","year":"2026"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1080\/14737167.2022.2079498","article-title":"Cost-effectiveness analysis of donafenib versus lenvatinib for first-line treatment of unresectable or metastatic hepatocellular carcinoma","volume":"22","author":"Meng","year":"2022","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1111\/liv.14257","article-title":"Cost-effectiveness analysis of cabozantinib as second-line therapy in advanced hepatocellular carcinoma","volume":"39","author":"Liao","year":"2019","journal-title":"Liver Int"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1002\/cac2.12110","article-title":"Atezolizumab plus bevacizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a cost-effectiveness analysis","volume":"40","author":"Hou","year":"2020","journal-title":"Cancer Commun (Lond)"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1172242","DOI":"10.3389\/fimmu.2023.1172242","article-title":"Cost-effectiveness analysis of serplulimab plus chemotherapy in the first-line treatment for Pd-L1-positive esophageal squamous cell carcinoma in China","volume":"14","author":"Liu","year":"2023","journal-title":"Front Immunol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"e210037","DOI":"10.1001\/jamanetworkopen.2021.0037","article-title":"Cost-effectiveness of atezolizumab plus bevacizumab vs sorafenib as first-line treatment of unresectable hepatocellular carcinoma","volume":"4","author":"Su","year":"2021","journal-title":"JAMA Netw Open"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"14871","DOI":"10.1002\/cam4.5724","article-title":"Cost-effectiveness analysis of sintilimab plus Ibi305 versus sorafenib for unresectable hepatic cell carcinoma in China","volume":"12","author":"Xu","year":"2023","journal-title":"Cancer Med"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s40273-024-01453-0","article-title":"Cost effectiveness of tremelimumab plus durvalumab for unresectable hepatocellular carcinoma in the USA","volume":"43","author":"Xiong","year":"2025","journal-title":"PharmacoEconomics"},{"key":"ref38","year":"2026"},{"key":"ref39","year":"2026"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"e094804","DOI":"10.1136\/bmjopen-2024-094804","article-title":"Cost-effectiveness of atezolizumab plus bevacizumab versus sorafenib as first-line therapy in unresectable hepatocellular carcinoma in the us and Chinese setting: a modelling comparison study","volume":"15","author":"Liu","year":"2025","journal-title":"BMJ Open"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1007\/s11096-024-01752-8","article-title":"Economic evaluation of camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma in the United States and China","volume":"46","author":"Wei","year":"2024","journal-title":"Int J Clin Pharm"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"e0196007","DOI":"10.1371\/journal.pone.0196007","article-title":"Assessment of costs associated with adverse events in patients with Cancer","volume":"13","author":"Wong","year":"2018","journal-title":"PLoS One"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"2598903","DOI":"10.1080\/07853890.2025.2598903","article-title":"A cost-effectiveness analysis of a new and more effective treatment for unresectable hepatocellular carcinoma-from a Chinese perspective","volume":"57","author":"Chen","year":"2025","journal-title":"Ann Med"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"1634266","DOI":"10.3389\/fpubh.2025.1634266","article-title":"Economic evaluation of anlotinib plus penpulimab vs. sorafenib as first-line therapy for unresectable hepatocellular carcinoma in China","volume":"13","author":"Fang","year":"2025","journal-title":"Front Public Health"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"778505","DOI":"10.3389\/fphar.2022.778505","article-title":"Sintilimab plus bevacizumab biosimilar versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a cost-effectiveness analysis","volume":"13","author":"Peng","year":"2022","journal-title":"Front Pharmacol"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1007\/s12325-022-02079-4","article-title":"Economic evaluation of sintilimab plus bevacizumab versus sorafenib as a first-line treatment for unresectable hepatocellular carcinoma","volume":"39","author":"Zhou","year":"2022","journal-title":"Adv Ther"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s40261-024-01343-5","article-title":"Cost-effectiveness analysis of camrelizumab plus rivoceranib versus sorafenib as a first-line therapy for unresectable hepatocellular carcinoma in the Chinese health care system","volume":"44","author":"Lang","year":"2024","journal-title":"Clin Drug Investig"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"2582294","DOI":"10.1080\/21645515.2025.2582294","article-title":"Cost-effectiveness analysis of anlotinib plus penpulimab versus sorafenib in the treatment of unresectable hepatocellular carcinoma","volume":"21","author":"Luo","year":"2025","journal-title":"Hum Vaccin Immunother"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1111\/liv.14795","article-title":"Atezolizumab and bevacizumab combination compared with sorafenib as the first-line systemic treatment for patients with unresectable hepatocellular carcinoma: a cost-effectiveness analysis in China and the United States","volume":"41","author":"Wen","year":"2021","journal-title":"Liver Int"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"17588359241274625","DOI":"10.1177\/17588359241274625","article-title":"Cost-effectiveness analysis of durvalumab plus tremelimumab as first-line therapy in patients with unresectable hepatocellular carcinoma","volume":"16","author":"Liao","year":"2024","journal-title":"Ther Adv Med Oncol"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"e090992","DOI":"10.1136\/bmjopen-2024-090992","article-title":"Tremelimumab plus durvalumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: a cost-effectiveness analysis from the us payer perspective","volume":"15","author":"Cheng","year":"2025","journal-title":"BMJ Open"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"e214846","DOI":"10.1001\/jamanetworkopen.2021.4846","article-title":"Cost-effectiveness of atezolizumab plus bevacizumab vs sorafenib for patients with unresectable or metastatic hepatocellular carcinoma","volume":"4","author":"Zhang","year":"2021","journal-title":"JAMA Netw Open"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1781790\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T04:21:05Z","timestamp":1783311665000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1781790\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":52,"alternative-id":["10.3389\/fpubh.2026.1781790"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2026.1781790","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]},"article-number":"1781790"}}